CA3200263A1 - Anti-sars-cov-2 antigen antibodies and related compositions and methods - Google Patents

Anti-sars-cov-2 antigen antibodies and related compositions and methods

Info

Publication number
CA3200263A1
CA3200263A1 CA3200263A CA3200263A CA3200263A1 CA 3200263 A1 CA3200263 A1 CA 3200263A1 CA 3200263 A CA3200263 A CA 3200263A CA 3200263 A CA3200263 A CA 3200263A CA 3200263 A1 CA3200263 A1 CA 3200263A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
set forth
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3200263A
Other languages
English (en)
French (fr)
Inventor
Erik Yusko
Peter J. R. EBERT
Amy Gilbert
Gladys KEITANY
Mark Klinger
Ben RUBIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adaptive Biotechnologies Corp
Original Assignee
Adaptive Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptive Biotechnologies Corp filed Critical Adaptive Biotechnologies Corp
Publication of CA3200263A1 publication Critical patent/CA3200263A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3200263A 2020-10-30 2021-10-29 Anti-sars-cov-2 antigen antibodies and related compositions and methods Pending CA3200263A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063108158P 2020-10-30 2020-10-30
US63/108,158 2020-10-30
US202063108791P 2020-11-02 2020-11-02
US63/108,791 2020-11-02
US202063112096P 2020-11-10 2020-11-10
US63/112,096 2020-11-10
US202163190097P 2021-05-18 2021-05-18
US63/190,097 2021-05-18
PCT/US2021/057452 WO2022094343A1 (en) 2020-10-30 2021-10-29 Anti-sars-cov-2 antigen antibodies and related compositions and methods

Publications (1)

Publication Number Publication Date
CA3200263A1 true CA3200263A1 (en) 2022-05-05

Family

ID=81384373

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3200263A Pending CA3200263A1 (en) 2020-10-30 2021-10-29 Anti-sars-cov-2 antigen antibodies and related compositions and methods

Country Status (8)

Country Link
US (1) US20230382979A1 (enExample)
EP (1) EP4237443A4 (enExample)
JP (1) JP2023548471A (enExample)
AU (1) AU2021369409A1 (enExample)
BR (1) BR112023008365A2 (enExample)
CA (1) CA3200263A1 (enExample)
IL (1) IL302460A (enExample)
WO (1) WO2022094343A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120981481A (zh) * 2023-01-10 2025-11-18 萨那生物技术股份有限公司 Cd19特异性抗体构建体以及它们的组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3538557A4 (en) * 2016-11-08 2020-11-18 Ablexis, LLC ANTI-CD47 ANTIBODY
WO2019075433A1 (en) * 2017-10-13 2019-04-18 Adimab, Llc ANTIBODIES AGAINST SYNCYTIAL RESPIRATORY VIRUS AND METHODS FOR THEIR GENERATION AND USE
CR20220552A (es) * 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno

Also Published As

Publication number Publication date
JP2023548471A (ja) 2023-11-17
EP4237443A4 (en) 2025-06-04
US20230382979A1 (en) 2023-11-30
WO2022094343A1 (en) 2022-05-05
IL302460A (en) 2023-06-01
BR112023008365A2 (pt) 2023-12-12
AU2021369409A9 (en) 2024-10-10
AU2021369409A1 (en) 2023-06-15
EP4237443A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
US20240174745A1 (en) Antibody Constructs for CLDN18.2 and CD3
JP7116256B1 (ja) 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片
CN110831965A (zh) 靶向hiv gp120和cd3的多特异性抗体
KR20180037950A (ko) 메소텔린 및 cd3에 결합하는 이중특이적 항체 작제물
CN110088131B (zh) 抗chikv抗体及其用途
US20240228596A1 (en) Pan-specific corona virus binders
US12509513B2 (en) Anti-L1CAM antibodies and uses thereof
US20200165354A1 (en) Novel Anti-PCSK9 Antibodies
JP7805362B2 (ja) Ｃｄ３に結合するポリペプチド構築物
US20230382979A1 (en) Anti-sars-cov-2 antigen antibodies and related compositions and methods
US20230406887A1 (en) Antigen binding domain with reduced clipping rate
CA3198333A1 (en) Antibody compositions for treatment of corona virus infection
US20260116983A1 (en) Anti-Urokinase-Type Plasminogen Activator Receptor Antibodies and Methods of Use
US20220332817A1 (en) Antibodies against human trem-1 and uses thereof
US20250382355A1 (en) Polypeptides effective against multiple coronaviruses
US20240391980A1 (en) Anti-Human Astrovirus Antibodies and Related Compositions and Methods
CA3107192C (en) Antibody constructs for cldn18.2 and cd3
HK40125826A (en) Anti-l1cam antibodies and uses thereof
EP4727583A1 (en) T cell engager masking molecules
WO2025083216A1 (en) Antibodies specific for the spike protein of sars cov-2 coronavirus
IL324608A (en) Antibody variable domains and antibodies having decreased immunogenicity
EA050517B1 (ru) Антигенсвязывающий домен с пониженной скоростью расщепления
HK40017754A (en) Multispecific antibodies that target hiv gp120 and cd3

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241007

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241007

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251006

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251006

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260428